Search Results - "Fetisova, Anna"
-
1
Reconstruction of the Magma Transport Patterns in the Permian-Triassic Siberian Traps from the Northwestern Siberian Platform on the Basis of Anisotropy of Magnetic Susceptibility Data
Published in Minerals (Basel) (01-03-2023)“…Patterns of magma transport during the emplacement of Large Igneous Provinces (LIPs) are extremely important for the understanding of their formation. The…”
Get full text
Journal Article -
2
Linking Siberian Traps LIP Emplacement and End-Permian Mass Extinction: Evidence from Magnetic Stratigraphy of the Maymecha-Kotuy Volcanic Section
Published in Geosciences (Basel) (01-08-2020)“…The Siberian Traps Large Igneous Provinces (LIP) emplacement is considered as one of possible triggers for the end-Permian global biotic crisis. However,…”
Get full text
Journal Article -
3
Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data
Published in Frontiers in pediatrics (22-02-2023)“…A significant number of systemic juvenile idiopathic arthritis (sJIA) patients discontinue biologic disease-modifying antirheumatic drugs (bDMARDs) due to lack…”
Get full text
Journal Article -
4
Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study
Published in Frontiers in medicine (15-11-2023)“…Introduction The blockade of interleukine-1 (anakinra and canakinumab) is a well-known highly effective tool for monogenic autoinflammatory diseases (AIDs),…”
Get full text
Journal Article -
5
Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method
Published in Modern rheumatology (03-09-2019)“…Objective: The aim of this study was to analyze the efficacy and safety of etanercept (ETA) in children with juvenile idiopathic arthritis (JIA) under the age…”
Get full text
Journal Article -
6
Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia
Published in Pediatric rheumatology online journal (14-06-2017)“…The aim of this study was to investigate the efficacy of etanercept treatment and to identify predictors of response to therapy within 12 months in patients…”
Get full text
Journal Article -
7
Effect of thermal induced stress of concrete on performance characteristics of constructions
Published in E3S Web of Conferences (01-01-2019)“…The article discusses issues related to determining and taking into account own thermally stressed state, which is formed in concrete during hardening, and is…”
Get full text
Journal Article Conference Proceeding -
8
Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate
Published in Pediatrics and neonatology (01-10-2019)“…Both the steroid- and NSAID-sparing effects of biologics in juvenile idiopathic arthritis (JIA) treatment are key aspects of the dynamics of patient's…”
Get full text
Journal Article -
9
Efficacy of Pneumococcal Polysaccharide Conjugate Vaccine (13-valent, Adsorbed) in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Genetically Engineered Biologic Drugs (Tocilizumab or Canakinumab): Prospective Cohort Study
Published in Voprosy sovremennoĭ pediatrii (10-08-2020)“…Background . Immunological potency of 13-valent pneumococcal vaccine (PCV-13) in children with systemic juvenile idiopathic arthritis (SJIA) is still…”
Get full text
Journal Article -
10
Effect of Monotherapy with Methotrexate, Etanercept and their Combination on the Quality of Life in Children with Early and Late Juvenile Idiopathic Arthritis: A Prospective Study
Published in Voprosy sovremennoĭ pediatrii (05-10-2018)“…Background. An important goal of treating patients with juvenile idiopathic arthritis (JIA) is to achieve the best quality of life associated with health…”
Get full text
Journal Article -
11
Early Prognostic Factors for Remission Achievement at Etanercept Therapy in Patients with Juvenile Idiopatic Arthritis Without Systematic Manifestations: Prospective Cohort Study
Published in Voprosy sovremennoĭ pediatrii (11-04-2019)“…Background . Prognosis of therapy results of patients with the juvenile idiopatic arthritis (JIA) without systematic manifestations is the precondition of…”
Get full text
Journal Article -
12
PROGNOSTIC FACTORS FOR THE RESPONSE TO TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS: A COHORT STUDY
Published in Voprosy sovremennoĭ pediatrii (16-07-2018)“…Background. To assign genetically engineered biologic drugs, we need data on the predictors for response to therapy. Prognostic factors for the response to…”
Get full text
Journal Article -
13
Early Predictors of the Response to Adalimumab Therapy in Patients With Juvenile Idiopathic Arthritis Without Systemic Manifestations: A Prospective Cohort Study
Published in Voprosy sovremennoĭ pediatrii (02-12-2018)“…Background. Tumour necrosis factor alpha inhibitors are widely used in the treatment of juvenile idiopathic arthritis (JIA). To achieve maximum efficiency of…”
Get full text
Journal Article -
14
Paleomagnetism of the Permian-Triassic intrusions from the Norilsk region (the Siberian platform, Russia): Implications for the timing and correlation of magmatic events, and magmatic evolution
Published in Journal of Asian earth sciences (01-09-2021)“…[Display omitted] •Intrusive magmatism in the Norilsk region occurred in 3 contrasting stages.•Main intrusive events corresponds to different volcanic…”
Get full text
Journal Article -
15
EFFICACY AND SAFETY OF ETANERCEPT TREATMENT IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS. THE RESULTS OF AN OPEN PROSPECTIVE STUDY ON THE BASIS OF THE SCIENTIFIC CENTER OF CHILDREN'S HEALTH (MOSCOW)
Published in Voprosy sovremennoĭ pediatrii (2016)“…Background: Addition of genetically engineered biological agents in the paradigm of juvenile idiopathic arthritis (JIA) treatment significantly increased the…”
Get full text
Journal Article -
16
P401 Dynamics of quality of life in children with idiopathic arthritis during etanercept therapy
Published in Archives of disease in childhood (01-06-2019)“…ObjectivesTo assess the influence of the genetically engineered biologic drug etanercept on the quality of life of patients with juvenile idiopathic arthritis…”
Get full text
Journal Article -
17
Paleomagnetism of trap intrusions, East Siberia: Implications to flood basalt emplacement and the Permo–Triassic crisis of biosphere
Published in Earth and planetary science letters (15-05-2014)“…Despite decades of concentrated studies, large igneous provinces (LIPs) are still among the most enigmatic phenomena of the Earth evolution. Among the myriad…”
Get full text
Journal Article -
18
Efficacy and safety of adalimumab as the first- and second-line biologic therapy for children with juvenile idiopathic arthritis under four years of age
Published in Egyptian rheumatologist (01-07-2020)“…New biologics developed to treat juvenile idiopathic arthritis (JIA) and the broadening range of indications for young children offer new drug switch options…”
Get full text
Journal Article -
19
Comparative Efficacy of Adalimumab and Etanercept in Children with Juvenile Idiopathic Arthritis Under 4 Years of Age Depending on Active Uveitis
Published in The open rheumatology journal (31-01-2019)“…Introduction: In 2011, Etanercept (ETA) was approved for clinical application in patients with Juvenile Idiopathic Arthritis (JIA) older than 2 years of age;…”
Get full text
Journal Article -
20
Switching to a Second TNF-_ Inhibitor in a Patient with Severe Juvenile Polyarthritis: A Clinical Case
Published in Voprosy sovremennoĭ pediatrii (05-10-2018)“…Background. Insufficient efficacy or intolerance of the first TNF-_ inhibitor in patients with juvenile idiopathic arthritis (JIA) is an indication for the…”
Get full text
Journal Article